This randomized, placebo and gold-standard controlled clinical trial, investigating the treatment of incipient buccal caries lesions with CURODONT™ REPAIR was recently published in Nature’s Scientific Reports.
Prof. Krejci and his team used asophisticatedstudy design to supply additional information relating to the performance of CURODONT™ REPAIR to standard clinical care, such as fluoride varnish or wait-and-see (i.e., placebo), as measured by the White Spot Lesion (WSL) size.
vVardis – the recently launched personal oral care brand by Dres Abivardi – has acquired credentis. credentis and vVardis previous partnership has already yielded the unique vVardis oral care product line, and now credentis will become the research and development department within vVardis.
Following the acquisition of credentis by vVardis, both the professional dental CURODONT™ line and the oral care vVardis products – both with the proprietary CUROLOX® & WX Technology – will form one oral care powerhouse. Within the newly formed partnership, credentis leadership team will continue to run credentis in order to accelerate the research and development of revolutionary oral care and dental products. For the credentis investors the acquisition by vVardis represents a successful exit, concluding a nearly decade long collaboration.
“I am overjoyed that we managed to establish credentis as an innovative dental and oral care company, that has become a successful investment case. Furthermore, with this acquisition the value generated will remain and support growth in Switzerland.”, says Dr Erich Platzer, former President of the Board of Directors of credentis, and lead investor for the business angel group, StartAngelsNetwork.
“This is a dream coming true – after 10 years of scientific research and development of our unique CUROLOX® TECHNOLOGY and the CURODONT™ products, we will take the next step – establishing the credentis and vVardis products in the dental and OTC markets.”, says Dr Dominik Lysek, CEO of credentis.
“For us, the combination of credentis’ scientific expertise and innovation, and our unique vVardis brand based on our expertise in Dentistry and Oral Care makes the perfect team to revolutionize the oral care and dental market with the best products possible.”, say the Dres Haleh and Golnar Abivardi, CEOs of vVardis.
CURODONT REPAIR in combination with fluoride varnish or CURODONT PROTECT is superior to the gold-standard fluoride varnish for treatment of initial caries as shown in yet another long-term, randomized, controlled clinical study. The new study conducted by Dr. Doberdoli and coworkers has now been published in the prestigious journal Scientific Reports.
Boston, MA, May 23, 2019 – credentis, a leader in state-of the art oral biology research and development, and DentaQuest, the nation’s leading purpose-driven oral health care organization, have entered into a strategic partnership to test and promote Curodont™ Repair Fluoride Plus and other Curolox® products in the North American Market, enabling better pre-cavity treatment and prevention for US consumers. Through this collaboration, DentaQuest will be the only US dental benefits company introducing these innovative products through DentaQuest’s national caries management partners and through its own preventive oral health centers. As part of its Preventistry® platform, DentaQuest Impact Inc. invests in innovative companies, technologies and products that have the potential to revolutionize oral health for everyone by redefining prevention and care. “In addition to giving Americans access to therapies that can promote the healing of teeth and reverse the progression of tooth decay before cavities form, we are excited to work with credentis to assess the preventive benefits of their existing products and help develop new ones that could help millions more live cavity free,” said Kirill Zaydenman, Vice President of Innovation for DentaQuest. “We believe credentis’ unique preventive technology has the potential to not only improve consumer health and enhance patient experience, but also lower the cost of care.”
“The partnership with DentaQuest provides an exceptional opportunity to demonstrate the benefit of credentis’ Curolox products – in particular the Guided Enamel Remineralization Therapy with Curodont Repair Fluoride Plus – and establish them in US dental practice.” said Dominik Lysek, CEO and founder of credentis ag.
This is the first investment of its kind for DentaQuest. According to Alison Corcoran, President of DentaQuest Impact Inc., “We have a long history of investing in oral health programs and research through the DentaQuest Partnership for Oral Health Advancement, and our support has helped drive positive change across the country for more than a decade, but this is different. To truly transform oral health, we need to also be partnering with – and investing in – many types of organizations, and we are thrilled to welcome credentis to the Preventistry® revolution.”
DentaQuest is a purpose-driven oral health care company that is dedicated to advancing oral health for all. We bring a uniquely holistic perspective to our work – as we manage dental and vision benefits for more than 27 million Americans and provide direct care to patients through our network of more than 85 oral health centers in five states. DentaQuest provides flexible and customized dental solutions for Medicaid and CHIP, Medicare Advantage, small and large businesses and individuals throughout the U.S. Our clients range from state governments to leading health plans.
At DentaQuest, we believe that business performance and social impact go hand-in-hand, and we have provided more than $200 million in funding for research, grants, and programs to advance oral health in communities across the country. Our mission is bold – our commitment is strong. By advancing oral health for everyone, we will achieve better health for all. Welcome to Preventistry.
credentis ag is headquartered in Switzerland. credentis has won multiple awards as well as multiple public grants include Swiss National Science Foundation (SNF), Aargauer Forschungsfonds, CTI, and the Medical Technologies IKC.
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman) contribute their pharma, medtech and dental industry expertise.
About Curodont™ and the Curolox®
The patented CUROLOX® is based on peptides self-assembling into a 3-dimensional matrix, triggering biomimetic mineralisation and repair from calcium, phosphate and fluoride. CUROLOX™ is the basis for all innovative credentis products. With its CURODONT™ product line, credentis supports the trend towards prevention and early treatment. CURODONT™ REPAIR & CURODONT™ REPAIR FLUORIDE PLUS provide dentists with a non-invasive option for natural in-depth mineralisation or Guided Enamel Remineralization (GER) which enables the regeneration of caries lesions and similar defects. CURODONT™ PROTECT uses CUROLOX® to protect the tooth surface from acid attack. CURODONT™ D’SENZ is optimised for the treatment of dentine hypersensitivity, to be used before dental hygiene treatment or in conjunction with tooth bleaching.
CURODONT REPAIR has shown to be superior to the gold-standard fluoride varnish in the treatment of initial caries as shown in a long-term, randomized, controlled clinical study. The new study conducted by Dr. Bröseler & Dr. Tietmann et. al. within their private practice, has recently been published in the prestigious journal Clinical Oral Investigations.
The clinical trial demonstrated significantly superior size reduction of the buccal white spot lesions after treatment with CURODONT REPAIR compared to those receiving fluoride varnish, which showed little change in size. In agreement with the size measurement, the researchers clinically assessed the white spots treated with CURODONT REPAIR to have regressed whereas control teeth were mainly unchanged, signifying the clinical benefit of the Guided Enamel Remineralization therapy with CURODONT REPAIR.
The strong Clinical Significance Statement by Dr Bröseler and co-workers highlights the potential of the novel remineralizing therapy in caries prevention: “P11-4 [CURODONT REPAIR] is the first caries treatment approach aiming to regenerate decayed enamel. […] adding a new advanced therapy option for preventive dentistry.“
Introducing CURODONT REPAIR FLUORIDE PLUS, a unique professional anti-cavity rinse for the non-invasive treatment of white spots. With the special CUROLOX formulation and application it acts where it is needed most, deep within the early carious lesion. Strengthening and remineralizing the entire enamel layer, it surpasses conventional fluoride products for anti-cavity treatment by far.
“We don’t have to imagine chemistry that
literally grows into the tooth, now we have it!”
Dr. Brian B. Nový, Director of Clinical Innovation, DentaQuest, Westborough,
in the US through our partner Straumann, as a cornerstone in the new Straumann® Preventive Dentistry portfolio.
Get in contact and learn more in how to differentiate your practice, increase chair time value and diversify your patient base with this new therapy. Click here and register on Straumann’s dedicated website.
credentis disclosed today that it has signed a non-exclusive distribution agreement with the Straumann Group for its non-invasive caries therapyCURODONT™ REPAIR. credentis’ unique product for Guided Enamel Regeneration will be launched as a key portfolio element for caries prevention and early caries treatment.
A randomized, placebo and gold-standard controlled clinical trial (RCT), investigating the treatment of incipient buccal caries lesions with CURODONT™ REPAIR was presented at the IADR 2018 in London. In this study Prof. Krejci and his team at the University of Geneva showed that the use of CURODONT™ REPAIR is superior to that of fluoride varnish (22’600ppm) or a placebo treatment.
By using the credentis pages and services, you agree to this use. Read More. Accept
Data Protection Declaration
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.